Tong Ren Tang Technologies Co. Ltd. (TGRNF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tong Ren Tang Technologies Co. Ltd. (TGRNF) trades at $0.49 with AI Score 48/100 (Grade C). Tong Ren Tang Technologies Co. Ltd. is a Chinese company specializing in the manufacture and sale of traditional Chinese medicine products. Market cap: $633.86M, Sector: Healthcare.
Last analyzed: Mar 15, 2026Analyst Coverage for TGRNF: TGRNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TGRNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TGRNF: the 1 perspectives are evenly split.
Tong Ren Tang Technologies Co. Ltd. (TGRNF) Healthcare & Pipeline Overview
Tong Ren Tang Technologies Co. Ltd., a manufacturer and seller of traditional Chinese medicine products, operates primarily in Mainland China and Hong Kong. With a history spanning over 350 years, the company cultivates raw materials, provides medical services, and faces competition from both domestic and international pharmaceutical companies.
What Is the Investment Thesis for TGRNF?
Tong Ren Tang Technologies Co. Ltd. presents a unique investment opportunity within the traditional Chinese medicine sector. With a P/E ratio of 10.97 and a dividend yield of 4.68%, the company offers potential value and income. A key value driver is the company's established brand and long history, dating back to 1669, which provides a competitive edge in the Chinese market. Growth catalysts include increasing demand for TCM products and expansion into new healthcare services. However, potential risks include regulatory changes in the pharmaceutical industry and competition from other TCM manufacturers. The company's gross margin of 39.8% and profit margin of 6.2% indicate profitability, but these margins could be vulnerable to fluctuations in raw material costs and pricing pressures.
Based on FMP financials and quantitative analysis
TGRNF Key Highlights
- Market capitalization of $0.70 billion, reflecting its position in the Chinese medicine market.
- P/E ratio of 10.97, suggesting a potentially undervalued investment relative to earnings.
- Dividend yield of 4.68%, providing a substantial income stream for investors.
- Gross margin of 39.8%, indicating the profitability of its product sales.
- Beta of 0.92, suggesting lower volatility compared to the overall market.
Who Are TGRNF's Competitors?
TGRNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARRJF Arjo AB (publ) | $2.96 | +0.00% | $807.58M | 43 |
| ELEAF EL.En. S.p.A. | $18.50 | +0.00% | $1.48B | 46 |
| EXETF Extendicare Inc. | $23.80 | +1.23% | $2.26B | 54 |
| GNMLF Genomma Lab Internacional, S.A.B. de C.V. | $1.08 | +0.00% | $1.06B | 52 |
| IDRSF Idorsia Ltd | $5.75 | +0.00% | $1.47B | 58 |
| FCAMX Franklin California High Yield Municipal Fund Class A1 | $9.73 | +0.00% | $3.29B | 51 |
| SIXD AllianzIM U.S. Equity 6 Month Buffer10 Jun/Dec ETF | $30.59 | -0.13% | $33.29M | 50 |
| FEDDX Fidelity Emerging Markets Discovery Fd | $22.82 | +2.98% | $1.55B | 47 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TGRNF's Key Strengths?
- Long-standing brand reputation and heritage.
- Extensive product portfolio of traditional Chinese medicines.
- Established distribution network in Mainland China and Hong Kong.
- Vertical integration from raw material sourcing to product sales.
What Are TGRNF's Weaknesses?
- Dependence on traditional Chinese medicine market.
- Limited geographic diversification beyond China and Hong Kong.
- Potential for quality control issues with raw materials.
- Exposure to regulatory changes in the pharmaceutical industry.
What Could Drive TGRNF Stock Higher?
- Potential regulatory approvals for new TCM products in development.
- Increasing demand for traditional Chinese medicine in both domestic and international markets.
- Expansion of e-commerce and online sales channels to reach a wider customer base.
What Are the Key Risks for TGRNF?
- Regulatory changes in the pharmaceutical industry that could impact the company's operations.
- Fluctuations in raw material costs that could affect profitability.
- Competition from other TCM manufacturers and pharmaceutical companies.
- Risk of counterfeit products that could damage the company's brand reputation.
- Dependence on the Chinese market and limited geographic diversification.
What Are the Growth Opportunities for TGRNF?
- Expansion into new geographic markets: Tong Ren Tang Technologies can expand its presence beyond Mainland China and Hong Kong by targeting overseas markets with significant Chinese diaspora populations. This expansion could involve establishing distribution partnerships or opening retail outlets in countries such as Singapore, Malaysia, and the United States. The global market for traditional medicine is estimated to be worth billions of dollars, offering substantial growth potential.
- Development of new TCM products: The company can invest in research and development to create new TCM products that cater to evolving consumer needs. This could include developing products that address specific health conditions or that are formulated using innovative extraction and processing techniques. The market for TCM products is constantly evolving, and companies that innovate can gain a competitive advantage.
- Integration of TCM with modern medicine: Tong Ren Tang Technologies can explore opportunities to integrate TCM with modern medicine by collaborating with hospitals and research institutions. This could involve conducting clinical trials to validate the efficacy of TCM treatments and developing integrated treatment protocols that combine TCM with conventional medical therapies. This integration could enhance the credibility and acceptance of TCM among healthcare professionals and patients.
- Expansion of healthcare services: The company can expand its healthcare services offerings by opening more TCM clinics and hospitals. These facilities can provide a range of services, including consultations, acupuncture, herbal medicine prescriptions, and other TCM therapies. The demand for TCM healthcare services is growing, driven by increasing consumer interest in natural and holistic healthcare solutions.
- E-commerce and online sales: Tong Ren Tang Technologies can strengthen its online presence and expand its e-commerce capabilities to reach a wider customer base. This could involve developing a user-friendly online store, offering online consultations with TCM practitioners, and implementing targeted marketing campaigns to promote its products and services. The e-commerce market in China is rapidly growing, and companies that can effectively leverage online channels can gain a significant competitive advantage.
What Opportunities Does TGRNF Have?
- Expansion into new geographic markets.
- Development of new TCM products and healthcare services.
- Integration of TCM with modern medicine.
- Growth in the e-commerce market for TCM products.
What Threats Does TGRNF Face?
- Competition from other TCM manufacturers.
- Regulatory changes affecting the pharmaceutical industry.
- Fluctuations in raw material costs.
- Potential for counterfeit products.
What Are TGRNF's Competitive Advantages?
- Established brand recognition and long history dating back to 1669.
- Extensive network of TCM clinics and hospitals.
- Proprietary formulations and manufacturing processes for TCM products.
- Access to high-quality Chinese medicinal raw materials.
What Does TGRNF Do?
Founded in 1669, Tong Ren Tang Technologies Co. Ltd. has evolved into a prominent manufacturer and distributor of traditional Chinese medicine (TCM) products. Originating as a supplier to the imperial court, the company has expanded its operations to include the cultivation and sourcing of Chinese medicinal raw materials, the production of various TCM products, and the provision of healthcare services. Its product portfolio includes traditional medicines, ointment, tea drinks, and foot care products. The company also engages in medical research and development, advertisement, and Chinese medical consultation and treatment services. Tong Ren Tang Technologies operates primarily in Mainland China and Hong Kong, focusing on both wholesale and retail sales of its products. The company has also diversified into the development and sale of biological products, Western medicines, cosmetics, and healthcare products. Additionally, it is involved in internal and external surgery, medical examination, and hospital management. The company's long history and established brand recognition provide a competitive advantage in the TCM market. The company employs 3991 individuals and is headquartered in Beijing, China.
What Products and Services Does TGRNF Offer?
- Manufactures and sells traditional Chinese medicine products.
- Cultivates and purchases Chinese medicinal raw materials.
- Produces and sells ointment, tea drinks, and foot care products.
- Provides medical research and development services.
- Offers Chinese medical consultation and treatment services.
- Sells biological products, Chinese and Western medicines, cosmetics, and healthcare products.
- Engages in hospital management activities.
- Processes biochemical products and extracts plants.
How Does TGRNF Make Money?
- Manufacturing and selling traditional Chinese medicine products through retail outlets and distributors.
- Cultivating and sourcing Chinese medicinal raw materials.
- Providing medical consultation and treatment services through TCM clinics and hospitals.
- Developing and selling biological products, cosmetics, and healthcare products.
What Industry Does TGRNF Operate In?
Tong Ren Tang Technologies operates within the traditional Chinese medicine (TCM) industry, which is experiencing growth driven by increasing consumer interest in natural and alternative healthcare solutions. The market is competitive, with numerous domestic and international players. The company's long history and established brand provide a competitive advantage. The global herbal medicine market is projected to reach billions of dollars in the coming years, presenting opportunities for expansion. Competitors include ARRJF (Ark Restaurants Corp), ELEAF (Eleaf USA Inc), and GNMLF (Genmab A/S).
Who Are TGRNF's Key Customers?
- Individuals seeking traditional Chinese medicine treatments.
- Hospitals and clinics that incorporate TCM into their services.
- Retail consumers purchasing TCM products for personal use.
- Distributors and wholesalers of pharmaceutical and healthcare products.
TGRNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating a belief in potential growth.
- Community sentiment has been increasingly positive, with many investors discussing the company's innovative product pipeline and expansion plans.
- The market has reacted favorably to Tong Ren Tang's recent partnerships, enhancing its brand visibility and market reach.
- Strong demand for traditional Chinese medicine has positioned the company well in a growing market, attracting attention from health-conscious consumers.
Bear Case
- Concerns about regulatory changes in the traditional medicine sector have raised doubts among some investors regarding future profitability.
- Community discussions reflect skepticism about the company's ability to scale operations effectively amid increasing competition.
- Recent earnings reports have shown mixed results, leading to uncertainty about the sustainability of its growth trajectory.
- Market perception remains cautious due to broader economic conditions impacting consumer spending on healthcare products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TGRNF Latest News
-
Global Penny Stocks With Market Caps Larger Than US$60M
Yahoo! Finance: TGRNF News · Jun 11, 2026
TGRNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TGRNF.
Price Targets
Wall Street price target analysis for TGRNF.
TGRNF MoonshotScore
What does this score mean?
The MoonshotScore rates TGRNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Yi Zhang
Unknown
Information on Yi Zhang's background is not available in the provided data. Details regarding his career history, education, and previous roles are currently unknown. Additional research would be required to provide a comprehensive profile of Mr. Zhang's professional experience and qualifications.
Track Record: Information on Yi Zhang's track record is not available in the provided data. Specific achievements, strategic decisions, and company milestones under his leadership are currently unknown. Further research would be needed to assess his impact on the company's performance and growth.
TGRNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Tong Ren Tang Technologies Co. Ltd. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and requires increased due diligence from investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited information availability due to the OTC Other tier.
- Lower liquidity and wider bid-ask spreads compared to major exchanges.
- Potential for price volatility due to limited trading volume.
- Increased risk of fraud or manipulation due to less regulatory oversight.
- Uncertainty regarding the company's financial health and operations.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Check for any red flags or warning signs, such as unusual trading activity or negative news.
- Consult with a financial advisor before making any investment decisions.
- Determine the availability and reliability of company information.
- The company has been in operation since 1669, indicating a long history.
- The company manufactures and sells traditional Chinese medicine products.
- The company employs 3991 individuals.
- The company has a market capitalization of $0.70 billion.
- The company has a dividend yield of 4.68%.
Tong Ren Tang Technologies Co. Ltd. Healthcare Stock: Key Questions Answered
What does Tong Ren Tang Technologies Co. Ltd. do?
Tong Ren Tang Technologies Co. Ltd. is primarily engaged in the manufacturing, marketing, and distribution of traditional Chinese medicine (TCM) products. The company also cultivates and sources Chinese medicinal raw materials. In addition to its core TCM business, Tong Ren Tang Technologies offers medical consultation and treatment services through its network of TCM clinics and hospitals. The company's products are sold through retail outlets, distributors, and online channels, targeting both domestic and international markets.
What do analysts say about TGRNF stock?
Analyst coverage of TGRNF is limited due to its OTC listing. However, key valuation metrics include a P/E ratio of 10.97 and a dividend yield of 4.68%. Growth considerations include the increasing demand for TCM products and the company's expansion into new markets and healthcare services. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks.
What are the main risks for TGRNF?
The main risks for TGRNF include regulatory changes in the pharmaceutical industry, fluctuations in raw material costs, competition from other TCM manufacturers, and the potential for counterfeit products. Additionally, the company's dependence on the Chinese market and limited geographic diversification pose risks. As an OTC-listed stock, TGRNF is subject to lower liquidity and greater price volatility than stocks listed on major exchanges.
What are the key factors to evaluate for TGRNF?
Tong Ren Tang Technologies Co. Ltd. (TGRNF) holds an AI score of 48/100 (low). P/E: 10.1x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does TGRNF data refresh on this page?
TGRNF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TGRNF's recent stock price performance?
Tong Ren Tang Technologies Co. Ltd. (TGRNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Long-standing brand reputation and heritage. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TGRNF overvalued or undervalued right now?
Tong Ren Tang Technologies Co. Ltd. (TGRNF) trades at 10.1x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying TGRNF?
Before investing in Tong Ren Tang Technologies Co. Ltd. (TGRNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC stocks carry additional risks due to limited regulation and disclosure.